ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Two membrane start-ups have closed successful investment rounds. TeraPore Technologies raised a total of $10 million from Anzu Partners, RA Capital Management, and the electronic materials firm Entegris. TeraPore CEO Rachel Dorin says the firm’s nanofiltration membranes are well suited to separate biologic drugs from fermentation-based production, a growing need in cutting-edge therapeutics. Meanwhile, SepPure Technologies raised $12 million in a series A round led by the venture capital firm SOSV. SepPure says its membranes can replace distillation in many industrial chemistry separations, achieving energy savings of up to 90%.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter